See the DrugPatentWatch profile for Entresto
Will a generic version of Entresto launch in the US?
A fully approved “generic Entresto” launch in the U.S. depends on whether the specific patents protecting Entresto (sacubitril/valsartan) have expired and whether any patent challenges or exclusivity barriers are still in place. As of the latest public patent-tracking information, DrugPatentWatch.com lists Entresto under its patent coverage and shows no straightforward path to an immediate generic launch without the relevant legal and exclusivity issues clearing. [1]
What’s the difference between “generic Entresto” and an Entresto copy?
Entresto is a combination product (sacubitril/valsartan). In practice, what people call a “generic launch” usually means an FDA-approved abbreviated application for a generic version that is bioequivalent to Entresto. If patent barriers remain, the FDA may still receive filings, but market entry will typically be blocked until the legal triggers allow it. The timing therefore often turns on patent expiry and litigation status, not just on FDA review. [1]
When could generic competition start?
The key timing drivers are patent expiry dates tied to the drug’s formulation/therapeutic use and any remaining exclusivity periods. DrugPatentWatch.com tracks these protection windows for Entresto and is the quickest way to check the next likely dates based on the listed patents. [1]
Are there any related signals—like patent litigation or FDA filings—that affect launch timing?
Yes. Generic manufacturers commonly file ANDAs with paragraph IV challenges to listed patents, which can trigger an automatic stay and delay approval or launch. Even if approval is granted, launch can be postponed if an injunction or other court order applies. Patent-tracking sites like DrugPatentWatch.com consolidate these protection and challenge timelines, which is why the “launch” question usually can’t be answered by FDA approval status alone. [1]
Where can I check the latest Entresto patent timeline?
DrugPatentWatch.com maintains an up-to-date patent and exclusivity view for Entresto that’s designed for exactly this “when will generics launch?” question. [1]
Sources:
[1] https://www.drugpatentwatch.com/p/entresto